用一个双胺抑制剂向导致1型肌性衰竭 (DM1) 的有毒RNA
Chun-Ho Wong1, Lien Nguyen, Jessie Peh
1Department of Chemistry, University of Illinois at Urbana-Champaign , 600 South Mathews Avenue, Urbana, Illinois 61801, United States.
Journal of the American Chemical Society
|April 8, 2014
概括
一种新型化合物 - - 联体3 - - 能够有效地破坏1型肌性衰竭 (DM1) 细胞中的毒性相互作用. 这一发现为通过恢复正常细胞功能来治疗DM1提供了有希望的新疗法.
科学领域:
- 分子生物学分子生物学
- 在RNA生物学,RNA生物学.
- 药物发现 药物发现 药物发现
背景情况:
- 肌性发育不良1型 (DM1) 病原体包括通过扩大CUG重复的MBNL1隔离.
- 抑制MBNL1-r ((CUG) ((exp) 相互作用是DM1.0的潜在治疗策略.
研究的目的:
- 发现和描述MBNL1-r(CUG) ((exp) 相互作用的抑制剂.
- 在DM1模型中评估已识别的抑制剂的治疗潜力.
主要方法:
- 合理的药物设计,以创建RNA槽结合抑制剂.
- 在体外结合试验 (K(d),K(i)) 评估连体亲和力和破坏MBNL1-r(CUG) 12相互作用.
- 基于细胞的测试用于评估DM1模型中的化合物透性,毒性和拼接恢复.
- 使用DM1Drosophila模型进行体内研究以评估治疗疗效.
主要成果:
- 确定了联体3,一个与bisamidinium相关的三氨酸化合物.
- 连接物3与低微分子亲和度的r(CUG) 12结合,并破坏MBNL1-r(CUG) 12的相互作用.
- 该化合物具有细胞透性,无毒,溶解核核点,并恢复DM1细胞模型中的拼接.
- 在DM1 Drosophila模型中,联体3抑制了RNA毒性.
结论:
- 干3有效地准DM1的分子机制.
- 该化合物在DM1.1的临床前模型中显示出治疗潜力.
- 干3代表了DM1药物开发的有前途的化合物.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
2.2K
Satellite Stem Cells and Muscular Dystrophy
1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Experimental RNAi
6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
RNA Interference
24.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K


